Idiopathic Pulmonary Fibrosis Concept

subject area of

• A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease  Journal Articles
• A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials  Journal Articles
• A novel ex vivo approach for investigating profibrotic macrophage polarization using murine precision-cut lung slices.  Journal Articles
• A novel profibrotic mechanism mediated by TGFβ‐stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells  Journal Articles
• A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity  Journal Articles
• A sudden deterioration in idiopathic pulmonary fibrosis  Journal Articles
• Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report  Journal Articles
• Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation  Journal Articles
• Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage  Journal Articles
• Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis  Journal Articles
• An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline  Journal Articles
• An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management  Journal Articles
• Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: the forgotten cell in COVID-19  Journal Articles
• Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone  Journal Articles
• Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis  Journal Articles
• Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?  Journal Articles
• Antifibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4–associated Tissue Repair Macrophages  Journal Articles
• Antifibrotic Role of αB-Crystallin Inhibition in Pleural and Subpleural Fibrosis  Journal Articles
• Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis  Journal Articles
• B Cells Are Not Involved in the Regulation of Adenoviral TGF-β1– or Bleomycin-Induced Lung Fibrosis in Mice  Journal Articles
• BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung Disease.  Journal Articles
• Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis  Conferences
• Cardiovascular Safety Of Nintedanib In Subgroups By Cardiovascular Risk At Baseline In The Tomorrow And Inpulsis Trials  Conferences
• Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis  Journal Articles
• Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis  Journal Articles
• Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease  Journal Articles
• Connective-Tissue Growth Factor Contributes to TGF-β1–induced Lung Fibrosis  Journal Articles
• Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease  Journal Articles
• Current models of pulmonary fibrosis for future drug discovery efforts  Journal Articles
• Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis  Journal Articles
• Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis  Journal Articles
• Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis  Journal Articles
• Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study  Journal Articles
• Diagnostic potential of genomic blood biomarkers of pulmonary fibrosis in a prospective cohort.  Journal Articles
• Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics  Journal Articles
• Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study  Journal Articles
• Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis  Journal Articles
• Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis  Journal Articles
• Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis  Journal Articles
• Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study  Journal Articles
• Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications  Journal Articles
• Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease  Journal Articles
• Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada  Journal Articles
• Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases  Journal Articles
• Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases  Journal Articles
• FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice  Journal Articles
• FK506-Binding Protein 13 Expression Is Upregulated in Interstitial Lung Disease and Correlated with Clinical Severity. A Potentially Protective Role  Journal Articles
• First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value  Journal Articles
• Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine  Journal Articles
• Heat shock protein: a hot topic in idiopathic pulmonary fibrosis  Journal Articles
• High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study  Journal Articles
• Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production  Journal Articles
• Identification of periplakin as a major regulator of lung injury and repair in mice  Journal Articles
• Idiopathic Pulmonary Fibrosis and Prothrombotic State Reply  Journal Articles
• Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side  Journal Articles
• Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?  Journal Articles
• Idiopathic pulmonary fibrosis – clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?  Journal Articles
• Idiopathic pulmonary fibrosis: idiopathic no more?  Journal Articles
• Idiopathic pulmonary fibrosis: state of the art for 2023  Journal Articles
• Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis  Journal Articles
• Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease  Journal Articles
• Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort  Journal Articles
• Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of β1,3-glucuronosyltransferase I in pulmonary fibrosis  Journal Articles
• Inflammation and dysregulated fibroblast proliferation--new mechanisms?  Journal Articles
• Influence of lung extracellular matrix from non-IPF and IPF donors on primary human lung fibroblast biology.  Journal Articles
• Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship  Journal Articles
• Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.  Conferences
• Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.  Journal Articles
• Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective  Journal Articles
• Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis  Journal Articles
• Lung cancer in pulmonary fibrosis: no room for nihilism!  Journal Articles
• Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis  Journal Articles
• Lysyl Oxidase–Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-β1–induced Pulmonary Fibrosis  Journal Articles
• Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension  Journal Articles
• Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis?  Journal Articles
• Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease  Journal Articles
• Matrix abnormalities in pulmonary fibrosis  Journal Articles
• Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis  Journal Articles
• Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis  Journal Articles
• Molecular breath analysis for IPF: Can we make a few breaths count?  Journal Articles
• Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers  Journal Articles
• Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis  Journal Articles
• Myeloid‐specific deletion of activating transcription factor 6 alpha increases CD11b⁺ macrophage subpopulations and aggravates lung fibrosis  Journal Articles
• Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease  Journal Articles
• New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research  Journal Articles
• Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)  Journal Articles
• Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases  Journal Articles
• Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial  Journal Articles
• Nintedanib in Progressive Fibrosing Interstitial Lung Diseases  Journal Articles
• Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume  Journal Articles
• Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial  Journal Articles
• Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial  Journal Articles
• Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis  Journal Articles
• Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib  Journal Articles
• Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?  Journal Articles
• Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions  Journal Articles
• Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis  Journal Articles
• Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)  Journal Articles
• Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis  Journal Articles
• Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases  Journal Articles
• Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease  Journal Articles
• Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry  Journal Articles
• Prognostic factors associated with mortality in acute exacerbations of idiopathic pulmonary fibrosis: A systematic review and meta-analysis  Journal Articles
• Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?  Journal Articles
• Progressive pulmonary fibrosis: an expert group consensus statement  Journal Articles
• Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report  Journal Articles
• Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis  Journal Articles
• R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life  Journal Articles
• Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3  Journal Articles
• Regulatory T Cells Limit Pneumococcus-Induced Exacerbation of Lung Fibrosis in Mice  Journal Articles
• Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?  Journal Articles
• Repetitive invasive lung function maneuvers do not accentuate experimental fibrosis in mice  Journal Articles
• Reply to “An Important Step Forward, but Still a Way to Go” and “Idiopathic Pulmonary Fibrosis and Prothrombotic State”  Journal Articles
• Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?  Journal Articles
• Reply: Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?  Journal Articles
• Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice  Journal Articles
• Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia  Conferences
• Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis  Journal Articles
• Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis  Journal Articles
• Staging of idiopathic pulmonary fibrosis: past, present and future  Journal Articles
• Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis  Journal Articles
• Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis  Journal Articles
• Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis  Journal Articles
• TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signalling  Journal Articles
• The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD  Journal Articles
• The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis  Journal Articles
• The importance of interventional timing in the bleomycin model of pulmonary fibrosis  Journal Articles
• The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?  Journal Articles
• The justification for the progressive fibrotic phenotype  Journal Articles
• The natural history of progressive fibrosing interstitial lung diseases  Journal Articles
• The small heat‐shock protein αB‐crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis  Journal Articles
• Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials  Journal Articles
• Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease  Journal Articles
• Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases  Journal Articles
• Therapeutic targets and early stage clinical trials for pulmonary fibrosis  Journal Articles
• Therapeutic targets in idiopathic pulmonary fibrosis  Journal Articles
• Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease  Journal Articles
• Treating IPF—all or nothing? A PRO‐CON debate  Journal Articles
• Treatment Initiation in Patients with Interstitial Lung Disease in Canada  Journal Articles
• Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update  Journal Articles
• Treatment of idiopathic pulmonary fibrosis: a network meta-analysis  Journal Articles
• Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials  Journal Articles
• Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis  Journal Articles
• Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns  Journal Articles
• VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats  Journal Articles
• Vascular–Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling  Conferences
• What have we learned from basic science studies on idiopathic pulmonary fibrosis?  Journal Articles
• What's in a name? That which we call IPF, by any other name would act the same  Journal Articles
• Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis  Journal Articles
• miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis  Journal Articles